Company news
Recce Pharmaceuticals Ltd. (ASX:RCE) news
Recce Pharmaceuticals Ltd. news releases on 6ix. Latest, Jul 15, 2024: US Department of Defense Grants US $2m for R327G
Press releases — page 2
US Department of Defense Grants US $2m for R327G
July 15, 2024
R327 Efficacy against WHO Priority Pathogen Acinetobacter B
July 8, 2024
Placement & SPP to raise $10 million - Funded to FY26
July 2, 2024
Phase I/II UTI/Urosepsis Rapid Infusion Trial Complete
June 27, 2024
Ethics Approval Broadens to All Topical Infections
June 24, 2024
Further R&D Rebate Approved
June 18, 2024
R327 added to WHO List of Antibacterial Products
June 18, 2024
Cohort Dosing Complete Ph I/II UTI/Urosepsis Clinical Trial
June 10, 2024
Ph I/II UTI/Urosepsis Trial Dosing Commenced in Next Cohort
May 15, 2024
MCRI Pilot Study- Positive Efficacy Data for Lung Infections
May 9, 2024
China Patent Granted for RECCE Anti-Infectives
May 6, 2024
Safety Committee Approves High Dose of 4,000mg
April 26, 2024
Recce Completes 5,000 R327 Doses Per Week under GMP
April 16, 2024
Recce Pharmaceuticals - Business Update
April 7, 2024
Patent Granted in Israel for RECCE Anti-Infectives
April 2, 2024
Next Cohort Dosing Ph I/II UTI/Urosepsis Clinical Trial
March 12, 2024
Recce Receives AUD $11.17m R&D Advance
March 7, 2024
Safety Committee Approves Expansion of Ph I/II DFI Trial
February 25, 2024
RCE Establishes Strategic Partnership in South-East Asia
February 5, 2024
Positive Ph I/II DFI Efficacy Data to Support Site Expansion
January 17, 2024
Murdoch Children's R327 Efficacy UTI in-vivo
December 27, 2023
RCE Awarded Further $11.17m Advanced Overseas Finding
December 15, 2023
RCE Awarded $43.7m AusIndustry Advanced Overseas Finding
December 14, 2023
Murdoch Children's R327 Efficacy N.gonorrhoeae in-vivo
December 13, 2023
Canadian Patent Granted for RECCE Anti-Infectives
November 22, 2023
Subjects Dosed Over 15 mins in UTI/Urosepsis Clinical Trial
November 6, 2023
Committee Approves Fast 15-Min Infusion in Ph I/II Urosepsis
October 23, 2023
Completes Cohort Dosing UTI/Urosepsis Rapid Infusion Trial
September 22, 2023
Placement and Entitlement Offer
September 11, 2023
Opening R&D Address at World AMR Congress
September 7, 2023
RECCE Trademark Registered - Vietnam
September 6, 2023
Additional Positive Patient Cases - Special Access Scheme
August 31, 2023
Appendix 4E and Unaudited Preliminary Report
August 31, 2023
Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial
August 28, 2023
Patients Dosed in R327 Diabetic Foot Infection Trial
August 22, 2023
Phase I/II Burn Wound Infection Trial Stage 1 Complete
August 21, 2023
Positive Patients Update - Special Access Scheme
August 7, 2023
Australian Patent Granted for RECCE Anti-Infectives
August 3, 2023
Bonus Canadian R&D Rebate Received
July 28, 2023
Scientia Completes Cohort Dosing in Phase I/II UTI Trial
July 28, 2023
Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
July 24, 2023
Clarification - 5x Higher Concentration in Urine & Plasma
July 20, 2023
Phase I Clinical Trial Data Review Complete
July 19, 2023
A$801,604 R&D Rebate Advance Received
July 12, 2023
First Cohort Dosed in Rapid Infusion Phase I/II UTI study
July 10, 2023
Ethics Approval for Phase I/II UTI Trial Expansion
June 29, 2023
Ethics Approval to Start Phase I/II (I.V.) Clinical Trial
April 17, 2023
New Family 4 Patent to be Granted for RECCE Anti-Infectives
April 10, 2023
Recce Receives Further A$973,144 R&D Advance
April 4, 2023
Corporate Presentation - WI Emergence 2023
March 22, 2023